OPIOID-FREE ANALGESIA IN ICU IN INTENSIVE CARE UNIT

• Status: Not yet recruiting
• Trial end date: 2025-04-01
• Target enrollment: 0
• Participant gender: All

Summary

ICU patients experience moderate to severe pain. Studies and guidelines point out the benefits of multimodal analgesia on pain control, opioid spare and on lowering its adverse effects. However, no recommendation about drugs or protocol has been formulated. In our study, we studied the feasibility and the impact on Remifentanil spare of a standardized protocol using multimodal analgesia (Paracetamol, Nefopam, Tramadol, Ketamine, Remifentanil) compared to the standard-of-care strategy using Paracetamol and Remifentanil. We conducted a prospective, ''proof of concept'', randomized, double-blind, parallel group, placebo-controlled trial. We studied multimodal analgesia versus standard-of-care in ICU patients requiring sedation-analgesia for invasive mechanical ventilation.We hypothesized that Remifentanil consumption decrease by 15% with the use of a standardized multimodal analgesia strategy

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Centre Hospitalier Universitaire de Nīmes

Criteria

Inclusion Criteria:

• Patient hospitalized in ICU and requiring sedation-analgesia for mechanical ventilation.

• Patient undergoing mechanical ventilation for more than 2 hours and less than 24 hours.

• Informed consent signed by the patient or his trusted person, legal representative, family member, curator or tutor, or emergency consent procedure.

• Patient affiliated to the French Government Public Health Insurance.

• Patient over 18 years old.

Exclusion Criteria:

• Patient already involved in a trial that might influence our primary endpoint.

• Patient in exclusion-period determined by another trial or study.

• Patient who is likely to be requiring less than 72 hours of mechanical ventilation.

• Patient with contraindication or allergies to at least one of the following medication : paracetamol, nefopam, tramadol, ketamine, remifentanil.

• Patient with hepatic insufficiency (defined as PT < 50%).

• Parturient or breast-feeding patient.

• Patient suffering from moderate to severe Acute Respiratory Distress Syndrome (ARDS), with decreased PaO2/FiO2 ratio under 150mmHg after respiratory optimization (courant volume 6mL/kg and PEEP > 5mbar).

• Patient requiring curare treatment.

• Patient requiring ICU after undergoing major surgery (laparotomy or thoracotomy).